Loading
A clinically accredited blood test for the four common KRAS mutations found tumour DNA in half of 59 patients before surgery and predicted recurrence afterwards with 90% sensitivity, about three months before the scan.
Digital droplet PCR was used in a CLIA and CAP-certified laboratory to detect the major pancreatic KRAS mutations (G12D, G12V, G12R, Q61H) in liquid biopsies, with 290 preoperative and longitudinal postoperative plasma samples from 59 patients. ctDNA was detected preoperatively in 29 (49%) and independently predicted decreased recurrence-free and overall survival. Patients who had neoadjuvant chemotherapy were less likely to have preoperative ctDNA (21% versus 69%). Levels dropped after resection; persistence immediately afterwards went with a high recurrence rate and median recurrence-free survival of 5 months. ctDNA during follow-up predicted recurrence with 90% sensitivity and 88% specificity at a median lead time of 84 days; detection during follow-up gave median overall survival 17 months against not reached at 30 months.
It shows a KRAS ctDNA test can be run to clinical laboratory standards in this disease, and it quantifies the lead time a surveillance programme would gain.
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Clinical Cancer Research, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares Signatera, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).